> Details

Malchers, Florian; Ercanoglu, Meryem; Schütte, Daniel; Castiglione, Roberta; Tischler, Verena; Michels, Sebastian; Dahmen, Ilona; Brägelmann, Johannes; Menon, Roopika; Heuckmann, Johannes M.; George, Julie; Ansén, Sascha; Sos, Martin L.; Soltermann, Alex; Peifer, Martin; Wolf, Jürgen; Büttner, Reinhard; Thomas, Roman K.

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer
  • Contributor: Malchers, Florian; Ercanoglu, Meryem; Schütte, Daniel; Castiglione, Roberta; Tischler, Verena; Michels, Sebastian; Dahmen, Ilona; Brägelmann, Johannes; Menon, Roopika; Heuckmann, Johannes M.; George, Julie; Ansén, Sascha; Sos, Martin L.; Soltermann, Alex; Peifer, Martin; Wolf, Jürgen; Büttner, Reinhard; Thomas, Roman K.
  • Published: American Association for Cancer Research (AACR), 2017
  • Published in: Clinical Cancer Research, 23 (2017) 18, Seite 5527-5536
  • Language: English
  • DOI: 10.1158/1078-0432.ccr-17-0478
  • ISSN: 1078-0432; 1557-3265
  • Origination:
  • Footnote:
  • Description: Abstract Purpose: The 8p12-p11 locus is frequently amplified in squamous cell lung cancer (SQLC); the receptor tyrosine kinase fibroblast growth factor receptor 1 (FGFR1) being one of the most prominent targets of this amplification. Thus, small molecules inhibiting FGFRs have been employed to treat FGFR1-amplified SQLC. However, only about 11% of such FGFR1-amplified tumors respond to single-agent FGFR inhibition and several tumors exhibited insufficient tumor shrinkage, compatible with the existence of drug-resistant tumor cells. Experimental Design: To investigate possible mechanisms of resistance to FGFR inhibition, we studied the lung cancer cell lines DMS114 and H1581. Both cell lines are highly sensitive to three different FGFR inhibitors, but exhibit sustained residual cellular viability under treatment, indicating a subpopulation of existing drug-resistant cells. We isolated these subpopulations by treating the cells with constant high doses of FGFR inhibitors. Results: The FGFR inhibitor–resistant cells were cross-resistant and characterized by sustained MAPK pathway activation. In drug-resistant H1581 cells, we identified NRAS amplification and DUSP6 deletion, leading to MAPK pathway reactivation. Furthermore, we detected subclonal NRAS amplifications in 3 of 20 (15%) primary human FGFR1-amplified SQLC specimens. In contrast, drug-resistant DMS114 cells exhibited transcriptional upregulation of MET that drove MAPK pathway reactivation. As a consequence, we demonstrate that rational combination therapies resensitize resistant cells to treatment with FGFR inhibitors. Conclusions: We provide evidence for the existence of diverse mechanisms of primary drug resistance in FGFR1-amplified lung cancer and provide a rational strategy to improve FGFR inhibitor therapies by combination treatment. Clin Cancer Res; 23(18); 5527–36. ©2017 AACR.
  • Access State: Open Access